Would you treat an early stage transformed DLBCL from indolent lymphoma in the same way as a standard, newly diagnosed de novo DLBCL?

To my knowledge, all studies in limited-stage LBCL excluded prior indolent lymphoma. Therefore, we do not have prospective data to support shorter courses of CIT. It will be an interesting subject of investigation. However, given that, in general, cell of origin or MYC double-hit status does not rea...